Innate Pharma S.A. Form 6-K Summary

Filing Date: November 5, 2025 Company: Innate Pharma S.A. (Foreign Private Issuer)

This Form 6-K filing confirms the submission of material information via Exhibit 99.1.

Investors must review Exhibit 99.1, the Press Release dated November 5, 2025, for details on potential financial updates, strategic developments, or regulatory news impacting the company.

• The report is signed by CEO Jonathan Dickinson.

• The company files reports under Form 20-F annually.

  Innate Pharma Q3 2025 Update Announcement

Innate Pharma (**IPH/IPHA